Patent Invalidation in Lyon

Patent invalidation Lyon strategy begins with a fact that surprises many local companies: no court in Lyon will ever hear the case. French patent validity is centralised by statute in Paris, roughly 400 kilometres away, so a Lyon business challenging a patent, or defending one, litigates in the capital. Yet the patents that matter here are shaped by the region — the vaccine and diagnostics work of the Lyonbiopôle cluster and the process chemistry of the Vallée de la chimie south of the city. PerspireIP builds nullity-grade prior-art and invalidity searches for generic entrants, biosimilar developers, diagnostics makers, chemical manufacturers and accused infringers operating out of the Lyon region.

Why patent invalidation Lyon cases are decided in Paris, not Lyon

The single most important fact about patent invalidation Lyon strategy is jurisdictional: no Lyon court hears it. Under Article L. 615-17 of the French Intellectual Property Code, the Tribunal judiciaire de Paris — the Paris Judicial Court — holds exclusive nationwide jurisdiction over the validity and infringement of French patents. A company headquartered in Lyon that wants to knock out a patent, or that is sued on one, litigates roughly 400 kilometres away in Paris rather than in its home city.

That centralisation is deliberate and long-standing. French patent disputes are concentrated in a specialised intellectual-property division of the Paris court, staffed by judges who hear nothing but IP cases. The French Supreme Court confirmed in 2015 that this competence is exclusive, so a validity challenge raised anywhere else — even by counterclaim in a commercial dispute filed in Lyon — must be transferred to Paris. Appeals from those decisions go to the Paris Court of Appeal.

For a Lyon defendant, three practical points follow from that single venue.

• Proceedings run in French, so foreign prior art and expert evidence must be translated to the court’s standard
• Validity and infringement are heard together by the same panel, with no German-style bifurcation and no injunction gap
• Local Lyon counsel almost always co-work with Paris-admitted litigators, and the evidence base has to satisfy a Paris IP judge

France sits inside the UPC, unlike its Swiss neighbour

Geography makes Lyon a genuine crossroads. It sits barely 150 kilometres from Geneva, yet the two cities operate under opposite systems. Switzerland is outside the European Union, the Unitary Patent and the Unified Patent Court; France is a founding UPC member and a Unitary Patent state. So a European patent covering France can now be attacked centrally: a single UPC revocation action can clear France and every other participating member state at once, which is impossible across the border in Switzerland.

The UPC map also runs through Paris. The court’s Central Division has its seat in Paris, and France operates a Paris local division for infringement actions. But the Central Division is split by technology: revocation actions on pharmaceuticals and other “human necessities” (IPC section A) are heard by the Milan section, chemistry and metallurgy patents (IPC section C) by the Munich section, while the Paris seat keeps physics, electronics and supplementary protection certificates.

For Lyon that split is not academic. Its two dominant industries land in two different UPC cities: a Lyon vaccine or diagnostics patent would be revoked in Milan, a Vallée de la chimie process patent in Munich. A defendant therefore chooses between a national nullity action in Paris, which clears only the French designation, and a UPC revocation, which clears the whole European bundle but is heard wherever the technology dictates.

Four attack routes and how they interact

A patent threatening a Lyon business is rarely vulnerable to only one attack. Depending on the patent’s age and type, an invalidity team can choose among four routes, and the calendar usually decides which is realistic.

• EPO opposition — filed at the European Patent Office within nine months of grant; it attacks the European patent centrally and reaches the French part along with every other designated state
• INPI opposition — since the 2020 PACTE reform, French patents granted from 1 April 2020 can be opposed before the INPI within nine months of grant, a lighter and cheaper administrative route than court
• French nullity action — brought at the Paris Judicial Court on the grounds in Article L. 613-25, and the only way to revoke the French part once the opposition windows have closed
• UPC revocation — for a Unitary Patent or the non-opted-out French part of a European bundle, heard in the relevant Central Division section

Sequencing is where teams slip. An EPO opposition is centrally efficient but can run for years, and a pending opposition does not automatically halt a French infringement suit in Paris. If a Lyon product is already on the market or a launch date is fixed, a national nullity action often has to run on its own timetable rather than waiting behind the EPO. We scope every viable route side by side at the outset, so the choice is made on evidence rather than on whichever deadline arrives first.

Lyon’s life-sciences cluster and what actually gets attacked

Lyon is one of Europe’s densest health-technology hubs, organised around the Lyonbiopôle competitiveness cluster and its 200-plus members. The city helped invent the modern vaccine: Sanofi’s vaccines business runs one of the planet’s largest vaccine sites at Marcy-l’Étoile just west of Lyon, bioMérieux leads globally in in-vitro diagnostics, and the Institut Mérieux, the homeopathy maker Boiron and Boehringer Ingelheim all anchor operations in the region.

That profile shapes the invalidity work. Original molecule patents have usually expired, so the fights that decide market entry are over the secondary layer built around them, and each type demands a different kind of prior art.

• Vaccine and biologics claims — antigens, adjuvants, expression systems and purification processes
• In-vitro diagnostic and assay patents, reagents, biomarkers and detection methods
• Second-medical-use and dosage-regimen claims
• Formulation, combination and delivery-device claims on injectors and inhalers

Killing these claims usually turns on non-patent literature rather than earlier patents: conference posters, clinical-trial registry entries, pharmacopoeia monographs, product labels, published regulatory material, doctoral theses and prior public use. A search that reaches those sources is worth far more to a Lyon life-sciences defendant than a longer list of patent hits, and it is the heart of most patent invalidation Lyon projects in the health sector.

The Vallée de la chimie and chemical-patent nullity

South of the city, along a ten-kilometre stretch of the Rhône, runs the Vallée de la chimie — one of Europe’s major chemical corridors. Roughly 500 companies and around 50,000 employees work there, concentrating close to a third of France’s chemistry research. Solvay, Arkema, Elkem Silicones, Kem One, Seqens and Daikin all run plants, R&D centres or headquarters along the valley, alongside a growing cleantech and green-chemistry base.

Chemical and materials patents fail on different evidence than biologics. Here the decisive disclosure is often buried in reaction conditions, process parameters and molecular structure rather than in a single headline claim.

• Process and catalyst claims, where a known reaction or an obvious optimisation defeats inventive step
• Markush and formulation claims that a single earlier disclosure can anticipate
• Polymer, silicone and specialty-chemical compositions
• Green-chemistry and lower-carbon production routes as the valley decarbonises

Because these patents fall in IPC section C, a UPC revocation would be heard by the Central Division’s Munich section rather than in Paris or Milan — a routing quirk worth confirming before a Lyon chemical maker fixes its forum. A national nullity action, by contrast, stays in the Paris Judicial Court regardless of the technology, and structure, Markush and reaction searching is what separates a defendable challenge from a hopeful one.

Grounds and evidence that win a French nullity action

French nullity is grounded in Article L. 613-25 of the Intellectual Property Code. A patent can be revoked where the invention is not patentable — lacking novelty, inventive step or industrial application, or falling within excluded subject matter — where it is insufficiently disclosed for a skilled person to carry it out, where its subject matter extends beyond the application as filed, or where the granted scope was unduly extended after grant.

In practice novelty and inventive step decide most cases, and both are anchored to the priority date. We map each asserted claim element by element, identify the date that actually governs it, and then search against that date rather than against the filing date printed on the cover page. French courts weigh inventive step in a way closely informed by the EPO’s problem-and-solution approach, so a record built for one forum supports the other without duplication.

One examination gap is worth remembering. The PACTE law only recently strengthened French prosecution — the INPI now reviews inventive step and runs its opposition procedure — but a large stock of older French patents was granted without a full inventive-step examination. Against those unexamined or lightly examined rights, a rigorous prior-art search does the work the office never did, which makes invalidity searching in Lyon unusually high-yield.

How PerspireIP builds a Lyon nullity-grade search

Every patent invalidation Lyon project starts the same way: we chart the asserted claims against the Article L. 613-25 grounds and the EPO problem-and-solution framework, then search from the priority date that actually governs each claim. From there the searching runs across global patent literature and, critically for the region’s pharmaceutical and chemical subject matter, across the non-patent sources where the decisive disclosure usually lives.

• Structure, Markush, sequence and reaction searching for chemistry and biologics claims
• Clinical-trial registries, conference abstracts, pharmacopoeias, labels and regulatory files
• French, German and English-language art that single-jurisdiction searches routinely miss
• A written invalidity opinion plus reference packages ready for the Paris court, the INPI, the EPO or the UPC

The deliverable is a record that a Paris IP judge or a UPC technical panel can follow, not a raw hit list. We work alongside your French patent attorneys and Paris litigators as a specialist search partner, deliver to court deadlines, and keep every engagement confidential — whether the assignment is a single freedom-to-operate blocker, an opposition at the INPI or the EPO, a UPC revocation, or a portfolio-wide campaign run from Lyon across the vaccine and chemical sectors.

IP Landscape & Resources in Lyon

Key intellectual-property authorities and venues relevant to Lyon:

• INPI (Institut National de la Propriété Industrielle) — France's national IP office; grants French patents and, since the PACTE law, hears nine-month post-grant oppositions
• Tribunal judiciaire de Paris — the Paris Judicial Court with exclusive nationwide jurisdiction over French patent validity and infringement
• Unified Patent Court — hears Unitary Patent and European-bundle revocation actions; its Central Division has its seat in Paris
• European Patent Office (EPO) — grants European patents validated in France and hears nine-month post-grant oppositions

Request a Patent Invalidation Search in Lyon

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions